Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Moderate Hepatic Impairment: early-phase trial registry
2 of 5 indexed Moderate Hepatic Impairment trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Moderate Hepatic Impairment: 5 US clinical trials tracked, 2 recruiting.
Moderate Hepatic Impairment is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Agios Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition moderate-hepatic-impairment
OPEN 2 | RECR 40% | LATE 0 | EARLY 5 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Moderate Hepatic Impairment lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Moderate Hepatic Impairment on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Moderate Hepatic Impairment is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Moderate Hepatic Impairment research.
Agios Pharmaceuticals accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Moderate Hepatic Impairment trials plan to enrol fewer than 100 people.
Median target enrolment is 20 among the 5 trials that report a genuine target (sentinel values excluded). 5 of those (100%) plan for fewer than 100 participants.
-
Moderate Hepatic Impairment research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Exelixis
NCT06962332
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
NCT07343960
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
Genfit
NCT05116826
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
Agios Pharmaceuticals
NCT05610657
A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)
Merck Sharp & Dohme
NCT04995484
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Moderate Hepatic Impairment records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Moderate Hepatic Impairment trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Moderate Hepatic Impairment page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Moderate Hepatic Impairment trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Agios Pharmaceuticals sponsors the most Moderate Hepatic Impairment trials on record, review their full trial history before evaluating a specific study. See Agios Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Moderate Hepatic Impairment condition card totals 5 registered trials; most-linked intervention Nitazoxanide; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.